DDInter630 DDInter1676
Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Elotuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paclitaxel
Elotuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Candida albicans
Elotuzumab {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Elotuzumab {u} may lead to a major life threatening interaction when taken with {v} Samarium (153Sm) lexidronam
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Elotuzumab may lead to a major life threatening interaction when taken with Fingolimod
Elotuzumab may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam